VCRE· Health Care› Biotechnology

Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. More about the company

$10.32

+11.21% today

$291M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

Steady

Edge

—

Is VCRE early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-07-06 → 2026-10-22

S? 16w

2026-07-062026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 16w current

Total tracked: 16 weeks across 1 stage run.

VCRE among Biotechnology588th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…588	VCREVicore Pharma Holding AB	—	—	+5.3%

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 16

1w13w26w

Week 16, proven structure

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

4.57x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+5.3%

-9.3%

—

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 16 · Vol 4.57x

2026-10-21S—

Wk 16 · Vol 0.41x

2026-10-20S—

Wk 16 · Vol 0.85x

2026-10-19S—

Wk 15 · Vol 0.16x

2026-10-16S—

Wk 15 · Vol 0.15x

2026-10-15S—

Wk 15 · Vol 1.82x

2026-10-14S—

Wk 15 · Vol 1.10x

2026-10-13S—

Wk 15 · Vol 1.36x

2026-10-12S—

Wk 14 · Vol 2.21x

2026-10-09S—

Wk 14 · Vol 1.63x

2026-10-08S—

Wk 14 · Vol 1.13x

2026-10-07S—

Wk 14 · Vol 1.77x

Moving averages & range

50 DMA

$10.46

200 DMA

—

52W High

—

52W Low

—

5D Low

$8.85

Resistance levels (recent highs)

20d High

$10.32

60d High

$12.93

120d High

—

250d High

—

Next resistance

+25.3%

to 60d High

ROE

-57.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B —

Vicore Pharma Holding AB: quick answers

Which sector and industry is Vicore Pharma Holding AB in?

Vicore Pharma Holding AB is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.